Genprex shares surge 11.31% premarket on positive preclinical data for REQORSA gene therapy and anticipation of upcoming business updates.

Genprex, Inc. (GNPX) surged 11.31% in premarket trading following positive preclinical data for its lead gene therapy candidate, REQORSA, highlighted at a major cancer therapeutics conference. The news generated significant social media buzz, with discussions emphasizing the stock's low float and high borrow rate, potentially amplifying price momentum. Institutional activity also added context, as Susquehanna and UBS increased holdings in Q2 2025, while recent congressional purchases by Representative Tim Moore further signaled confidence. The premarket rally aligns with expectations for upcoming business updates and financial results, reinforcing optimism around the biotech's pipeline advancements.